Overview

A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19

Status:
Active, not recruiting

Trial end date:
2022-07-12

Target enrollment:

Participant gender:

Summary

This study aims to evaluate the safety (in all participants) and reactogenicity (in a subset of participants) of CVnCoV administered as a 2-dose schedule to adult participants 18 years of age or older. The study also aims to assess antibody responses to the receptor-binding domain (RBD) of spike (S) protein of SARS-CoV-2 after 1 and 2 doses of CVnCoV in adults 18 years of age or older included in a subset of participants.

Phase:

Phase 3

Details

Lead Sponsor:

CureVac AG

Collaborator:

German Federal Ministry of Education and Research